These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1159 related articles for article (PubMed ID: 27127191)

  • 21. Chimeric switch receptor: switching for improved adoptive T-cell therapy against cancers.
    Tay JC; Zha S; Wang S
    Immunotherapy; 2017 Dec; 9(16):1339-1349. PubMed ID: 29185393
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CAR T-cell therapy of solid tumors.
    Yong CSM; Dardalhon V; Devaud C; Taylor N; Darcy PK; Kershaw MH
    Immunol Cell Biol; 2017 Apr; 95(4):356-363. PubMed ID: 28003642
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adverse Effects Associated with Clinical Applications of CAR Engineered T Cells.
    Badieyan ZS; Hoseini SS
    Arch Immunol Ther Exp (Warsz); 2018 Aug; 66(4):283-288. PubMed ID: 29427174
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adoptive T-cell therapy for cancer: The era of engineered T cells.
    Bonini C; Mondino A
    Eur J Immunol; 2015 Sep; 45(9):2457-69. PubMed ID: 26202766
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cellular immunotherapy for malignant gliomas.
    Lin Y; Okada H
    Expert Opin Biol Ther; 2016 Oct; 16(10):1265-75. PubMed ID: 27434205
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic.
    Duong CP; Yong CS; Kershaw MH; Slaney CY; Darcy PK
    Mol Immunol; 2015 Oct; 67(2 Pt A):46-57. PubMed ID: 25595028
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prospects for immunotherapy of acute myeloid leukemia using γδ T cells.
    Halim L; Parente-Pereira AC; Maher J
    Immunotherapy; 2017 Jan; 9(2):111-114. PubMed ID: 28128710
    [No Abstract]   [Full Text] [Related]  

  • 28. Genetically modulating T-cell function to target cancer.
    Merhavi-Shoham E; Haga-Friedman A; Cohen CJ
    Semin Cancer Biol; 2012 Feb; 22(1):14-22. PubMed ID: 22210183
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current status of engineered T-cell therapy for synovial sarcoma.
    Dallos M; Tap WD; D'Angelo SP
    Immunotherapy; 2016 Sep; 8(9):1073-80. PubMed ID: 27485079
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Engineering Hematopoietic Cells for Cancer Immunotherapy: Strategies to Address Safety and Toxicity Concerns.
    Resetca D; Neschadim A; Medin JA
    J Immunother; 2016 Sep; 39(7):249-59. PubMed ID: 27488725
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of adoptive cell therapy for cancer: a clinical perspective.
    Hawkins RE; Gilham DE; Debets R; Eshhar Z; Taylor N; Abken H; Schumacher TN; ATTACK Consortium
    Hum Gene Ther; 2010 Jun; 21(6):665-72. PubMed ID: 20408760
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treating cancer with genetically engineered T cells.
    Park TS; Rosenberg SA; Morgan RA
    Trends Biotechnol; 2011 Nov; 29(11):550-7. PubMed ID: 21663987
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Unleash the power of the mighty T cells-basis of adoptive cellular therapy.
    Sukari A; Abdallah N; Nagasaka M
    Crit Rev Oncol Hematol; 2019 Apr; 136():1-12. PubMed ID: 30878123
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TCR-engineered T cells to treat tumors: Seeing but not touching?
    Debets R; Donnadieu E; Chouaib S; Coukos G
    Semin Immunol; 2016 Feb; 28(1):10-21. PubMed ID: 26997556
    [TBL] [Abstract][Full Text] [Related]  

  • 35. T cell immunotherapy.
    McKee MD; Fichera A; Nishimura MI
    Front Biosci; 2007 Jan; 12():919-32. PubMed ID: 17127349
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cancer immunotherapy: moving forward with peptide T cell vaccines.
    Kumai T; Fan A; Harabuchi Y; Celis E
    Curr Opin Immunol; 2017 Aug; 47():57-63. PubMed ID: 28734176
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunotherapy for glioma: from illusion to realistic prospects?
    Dietrich PY; Dutoit V; Walker PR
    Am Soc Clin Oncol Educ Book; 2014; ():51-9. PubMed ID: 24857060
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetically redirected T lymphocytes for adoptive immunotherapy of solid tumors.
    Leuci V; Mesiano G; Gammaitoni L; Aglietta M; Sangiolo D
    Curr Gene Ther; 2014 Feb; 14(1):52-62. PubMed ID: 24365144
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Principles of adoptive T cell therapy in cancer.
    Met Ö; Jensen KM; Chamberlain CA; Donia M; Svane IM
    Semin Immunopathol; 2019 Jan; 41(1):49-58. PubMed ID: 30187086
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Engineering T cells for adoptive therapy: outsmarting the tumor.
    Kunert A; Debets R
    Curr Opin Immunol; 2018 Apr; 51():133-139. PubMed ID: 29579622
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 58.